MKMarcela Kreslová

Marcela Kreslová

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcela Kreslová has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Josef Sýkora

    Department of Paediatrics University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague Czech Republic

    6 shared publications
  • Jan Baxa

    Department of Imaging Methods, NH Hospital, AKESA Holding

    4 shared publications
  • Hana Hrdinová

    Department of Imaging Methods, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

    3 shared publications
  • Veronika Schwarzová

    Department of Paediatrics University Hospital, Faculty of Medicine in Pilsen, Charles University in Prague Prague Czech Republic

    3 shared publications
  • Václav Koucký

    Department of Paediatrics, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

    3 shared publications
  • Aneta Sýkorová

    Charles University in Prague, Faculty of Medicine in Pilsen, Faculty Hospital, Department of Paediatrics , Pilsen, Czech Republic

    2 shared publications

Latest Publications

  • Open Access

    Clinical benefit without sweat chloride response after ETI therapy in an adult with cystic fibrosis bearing the L467F;F508del complex CFTR allele: a case report and the role of AI-assisted chest CT in longitudinal monitoring

    by Marcela Kreslova, Daan Caudri, Isabelle Sermet-Gaudelus, Aurelie Hatton, Punitkumar Makani, Vaclav Koucky, Malgorzata Libik, Hana Hrdinova, Libor Fila, Nela Stastna, et al.

    Background: Elexacaftor/tezacaftor/ivacaftor (ETI) is the standard of care for most people with cystic fibrosis (CF) who carry at least one F508del allele. However, predicting responses to CFTR modulators in rare or complex CFTR genotypes is challenging. Sweat chloride concentration (SCC) and patient-derived functional assays assessing CFTR-mediated chloride transport are commonly used to classify modulator responsiveness. Carriers of the p.Leu467Phe;p.Phe508del (henceforward legacy nomenclature: L467F;F508del) complex CFTR allele have been considered unlikely to respond to ETI, based on short-term clinical, biomarker and ex vivo evidence. We report a discordant long-term response in an adult carrying this complex allele, with clinically meaningful benefit despite persistently negative CFTR chloride transport biomarkers. Case presentation: We describe an 8-year longitudinal pre- and post-treatment assessment of an adult woman with CF, adherent to therapy, with the L467F;F508del complex allele compounded with the non-responsive c.489 + 1G > T (621 + 1G > T) variant in trans . She has pancreatic insufficiency, progressive lung disease, and recurrent pulmonary exacerbations. After ETI commencement (at 40.5 years; July 2021) SCC remained unchanged at ∼100 mmol/L. Intestinal organoid and primary nasal epithelial cell assays showed no measurable ETI-related CFTR-mediated chloride transport rescue. Nevertheless, BMI increased from 22.0 to 26.8 kg/m 2 , annual exacerbations decreased from 5 to 3, and ppFEV₁ improved from 51% to 55–59%. Serial chest CT showed a shift from pre-ETI progression to post-ETI stabilisation, with reductions in air trapping and the extent of bronchiectasis on manual Brody II scoring and LungQ/PRAGMA-AI quantification. Exploratory in vitro exposure of nasal epithelial cells to vanzacaftor/tezacaftor/ivacaftor yielded ∼5% CFTR-mediated rescue, contrasting with the negative ETI response. Conclusion: Persistent CFTR biomarker negativity may not fully exclude clinically meaningful ETI-associated benefit in rare or complex CFTR genotypes. The pulmonary and extrapulmonary improvements observed in this case support multidimensional response assessment beyond single-biomarker endpoints. These hypothesis-generating observations support individualised long-term monitoring and comprehensive interpretation of CFTR biomarkers in the clinical context. AI-assisted chest CT may provide complementary real-world evidence. An exploratory in vitro rescue study with vanzacaftor/tezacaftor supports the evaluation of emerging CFTR modulators. It suggests that similar studies should be conducted in other cases involving complex CFTR alleles.

  • Pica‐Induced Airway Obstruction in Paediatric Cystic Fibrosis: An Unexpected Culprit

    by Anna Šmejkalová, Václav Koucký, Josef Sýkora, Hana Hrdinová, Jana Bartošová, Jan Baxa, Marcela Kreslová

  • Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abscessus Eradication in a Child With Cystic Fibrosis

    by Marcela Kreslová, Josef Sýkora, Veronika Skalická, Hana Hrdinová, Jana Amlerová, Romana Kaslová, Jan Baxa, Veronika Schwarzová, Václav Koucký

  • Open Access

    Elexacaftor/Tezacaftor/Ivacaftor for Mycobacterium abs. Eradication in a Child with Cystic Fibrosis

    by Marcela Kreslová, Sýkora J., Veronika Skalicka, Hana Hrdinová, Jana Amlerová, Romana Kaslová, Jan Baxa, Schwarzová V., Vaclav Koucky

  • Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis

    by Veronika Schwarzová, Jan Schwarz, Katarina Mitrová, Pavel Dřevínek, Marcela Kreslová, Josef Sýkora, Tereza Doušová

    We report the first described case of pulmonary tularaemia in the pediatric patient receiving infliximab for ulcerative colitis. We highlight the importance of considering Francisella tularensis in diagnostically challenging cases of persistent respiratory symptoms to facilitate early diagnosis and adequate therapy. The TCR‐γδ + DN T cells are gaining important role in clinical practice. Polymerase chain reaction assays and serology guarantee early recognition.


  • Open Access

    Circulating Serum Cystatin C as an Independent Risk Biomarker for Vascular Endothelial Dysfunction in Patients with COVID-19-Associated Multisystem Inflammatory Syndrome in Children (MIS-C): A Prospective Observational Study

    by Marcela Kreslová, Petr Jehlička, Aneta Sýkorová, Daniel Rajdl, Eva Klásková, Pavel Prokop, Sabina Kaprálová, Jan Pavlíček, Romana Kaslová, Alžběta Palátová, et al.

    Introduction: Multisystem inflammatory syndrome in children (MIS-C) is a new clinical entity that has emerged in the context of the COVID-19 pandemic. Despite the less severe course of the disease, varying degrees of cardiovascular events may occur in MIS-C; however, data on vascular changes occurring in MIS-C are still lacking. Endothelial dysfunction (ED) is thought to be one of the key risk factors contributing to MIS-C. Background: We conducted a prospective observational study. We investigated possible manifestations of cardiac and endothelial involvement in MIS-C after the treatment of the acute stage and potential predictive biomarkers in patients with MIS-C. Methods: Twenty-seven consecutive pediatric subjects (≥9 years), at least three months post-treated MIS-C of varying severity, in a stable condition, and twenty-three age- and sex-matched healthy individuals (HI), were enrolled. A combined non-invasive diagnostic approach was used to assess endothelial function as well as markers of organ damage using cardiac examination and measurement of the reactive hyperemia index (RHI), by recording the post- to pre-occlusion pulsatile volume changes and biomarkers related to ED and cardiac disease. Results: MIS-C patients exhibited a significantly lower RHI (indicative of more severe ED) than those in HI (1.32 vs. 1.80; p = 0.001). The cutoff of RHI ≤ 1.4 was independently associated with a higher cardiovascular risk. Age and biomarkers significantly correlated with RHI, while serum cystatin C (Cys C) levels were independently associated with a diminished RHI, suggesting Cys C as a surrogate marker of ED in MIS-C. Conclusions: Patients after MIS-C display evidence of ED, as shown by a diminished RHI and altered endothelial biomarkers. Cys C was identified as an independent indicator for the development of cardiovascular disease. The combination of these factors has the potential to better predict the cardiovascular consequences of MIS-C. Our study suggests that ED may be implicated in the pathophysiology of this disease.


  • Open Access

    Bronchial Asthma as a Cardiovascular Risk Factor: A Prospective Observational Study

    by Marcela Kreslová, Olga Kirchnerová, Daniel Rajdl, Vendula Sudová, Jiří Blažek, Aneta Sýkorová, Petr Jehlička, Ladislav Trefil, Jan Schwarz, Renata Pomahačová, et al.

    Introduction: Asthma as a chronic inflammatory disorder has been suggested as a risk factor for endothelial dysfunction (ED), but studies on the association between asthma and cardiovascular disease (CVD) risk are limited. Background: We assessed associations of ED with the severity of asthma, eosinophilic inflammation, lung function, and asthma control. Methods: 52 young asthmatics (median age of 25.22 years) and 45 healthy individuals were included. Demographic, clinical, and laboratory findings were recorded. We evaluated microvascular responsiveness by recording the reactive hyperemia index (RHI) indicating post-occlusive peripheral endothelium-dependent changes in vascular tone using the Itamar Medical EndoPAT2000. VCAM-1, ADMA, high-sensitive CRP (hsCRP), and E-selectin were measured. Results: Asthmatics had considerably lower RHI values (p < 0.001) with a dynamic decreasing trend by asthma severity and higher hsCRP levels (p < 0.001). A substantial increase in hsCRP and E-selectin with asthma severity (p < 0.05) was also observed. We confirmed a higher body mass index (BMI) in asthmatics (p < 0.001), especially in women and in severe asthma. Conclusions: We demonstrated the progression of CVD in asthmatics and the association of the ongoing deterioration of ED with the inflammatory severity, suggesting that the increased risk of CVD in young asthmatics is dependent on disease severity. The underlying mechanisms of risk factors for CVD and disease control require further study.


  • Age-Related Progression of Microvascular Dysfunction in Cystic Fibrosis: New Detection Ways and Clinical Outcomes

    by M Kreslová, A Sýkorová, R Bittenglová, J Schwarz, R Pomahačová, P Jehlička, J Kobr, L Trefil, J Sýkora

    There are concerns about altered vascular functions that could play an important role in the pathogenesis and influence the severity of chronic disease, however, increased cardiovascular risk in paediatric cystic fibrosis (CF) has not been yet fully understood. Aim was to analyze vascular disease risk and investigate changes over times in CF and controls. We prospectively enrolled 22 CF subjects (a median age of 16.07 years), and 22 healthy demographically matched controls (a median age of 17.28 years) and determined endothelial function. We utilized a combined diagnostic approach by measuring the plethysmographic Reactive Hyperemia Index (RHI) as the post-to preocclusive endothelium-dependent changes of vascular tone, and biomarkers that are known to be related to endothelial dysfunction (ED): asymmetric dimethyl arginine (ADMA), high-sensitive CRP (hsCRP), VCAM-1 and E-selectin. RHI values were significantly lower in CF young adults (p<0.005). HsCRP (p<0.005), E-selectin (p<0.001) and VCAM-1 (p<0.001) were significantly increased in CF patients since childhood. The findings have provided a detailed account of the ongoing process of microvascular dysfunction with gradual progression with the age of CF patients, making them further at risk of advanced vascular disease. Elevations of biomarkers in CF children with not yet demonstrated RHI changes but with significantly reduced RHI in adulthood and lipid profile changes indicate the possible occurrence of ED with CF-related specific risk factors over time and will enable us to provide the best possible support.


  • Endothelial dysfunction in children and adults with asthma – combined diagnostic approach

    by Marcela Kreslova, Aneta Sýkorová, Olga Kirchnerová, Petr Jehlička, Ladislav Trefil, Josef Sýkora

    Introduction: Endothelial dysfunction (ED) is an early functional preclinical manifestation of atherosclerosis. The patterns of ED and the risk of cardiovascular disease in patients with asthma are largely unknown. The aim of the study was to evaluate cardiovascular risk using a combined diagnostic approach by measuring Reactive Hyperemia Index (RHI) and specific biomarkers in patients with asthma compared to healthy controls (HC). Methods: A total of 52 astma subjects and 45 healthy controls were enrolled. We evaluated RHI using a new non-invasive plethysmographic method and measured plasma concentrations of four ED-related biomarkers: VCAM-1, ADMA, high-sensitive CRP (hsCRP) and E-selectin. Results: In the asthma group we found significantly lower RHI values (p<0.001) and a significant increase in hsCRP (p<0.01) as well as a decrease in ADMA (p<0.05) and VCAM-1 (p<0.01). We showed a statistically significant increase in hsCRP by type of asthma (p<0.05), a decrease in ADMA and E-selectin with allergic asthma severity (p<0.05), and a decrease in E-selectin relative to asthma control (p<0.01). We confirmed statistically significantly higher BMI in asthma group (p<0.001), more in women and in severe forms of asthma. Conclusions: The results of our study suggest a possible occurrence of ED in asthma patients associated with a higher risk of premature manifestation of atherosclerosis. Increased hsCRP in asthma patients suggests the importance of chronic systemic inflammatory process as a significant risk factor of ED. The conclusions show the possibility of using this method for the detection of ED and subsequent evaluation of cardiovascular risk in children and adults with asthma in the long term.

  • Rare cause of upper bowel obstruction arising in a 17‐year‐old boy with cystic fibrosis: Superior mesenteric artery (Wilkie's) syndrome

    by Jan Schwarz, Josef Sýkora, Renáta Pomahačová, Aneta Sýkorová, Jiří Fremuth, Lumír Šašek, Renáta Vondráková, Marcela Kreslová